Clinical Trial Update: Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a Phase 1/2 study of durvalumab with or without tremelimumab in resectable locally advanced oral cavity squamous cell carcinoma is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Cavity Squamous Cell Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Universitaire Ziekenhuizen KU Leuven | Conditions: Oral Cavity Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING